Catalyst

Slingshot members are tracking this event:

Lexicon Pharma (LXRX) Expects Commercial Launch of Telotristat Ethyl in Late Q1 for Patients with Carcinoid Syndrome

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
LXRX

100%
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Telotristat Ethyl, Carcinoid Syndrome